Aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease

American Journal of Cardiology

Volumn 86, Issue 2, 2000, Pages 250-252

  Isaacsohn, Jonathan L ^a   Davidson, Michael H ^b   Hunninghake, Donald ^c   Singer, Robert ^d   McLain, Richard ^d   Black, Donald M ^d  

^a Metabolic and Atherosclerosis Research Center   (United States)

^b RADIANT RESEARCH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; COST; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY;

EID: 0034085446     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)00872-9     Document Type: Article

References (13)

1. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 89:1994;1333-1445.
2. Wood D., de Backer G., Faergeman O., Graham I., Mancia G., Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J. 19:1998;1434-1503.
3. Martin M.J., Hulley S.B., Browner W.S., Kuller L.H., Wentworth D. Serum cholesterol, blood pressure and mortality implications from a cohort of 361,662 men . Lancet. 2:1986;933-936.
4. Verschuren W.M., Jacobs D.R., Bloemberg B.P., Kromhout D., Menotti A., Aravanis C., Blackburn H., Buzina R., Dontas A.S., Fidanza F., Karvonen M.J., Nedelijkovic S., Nissinen A., Toshima H. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA. 274:1995;131-136.
5. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
6. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
7. Sacks F.M., Pfeffer M.A., Moyé L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
9. Downs J.R., Clearfield Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622.
10. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 336:1997;153-162.
11. Pitt B., Waters D., Brown W.V., van Boven J., Schwartz L., Title L.M., Eisenberg D., Shurzinske L., McCormick L.S. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med. 341:1999;70-76.
12. Nawrocki J.W., Weiss S.R., Davidson M.H., Sprecher D.L., Schwartz S.L., Lupien P.J., Jones P.H., Haber H.E., Black D.M. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 15:1995;678-682.
13. Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 81:1998;582-587.